Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial ... and new data from EVOKE-1 is due to be presented at the ASCO congress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback